NCT07504796 2026-04-21
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
Phase 4 Recruiting
Clinical Trials
7 trialsNCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT02869789 2023-06-15
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Bristol-Myers Squibb
Phase 4 Completed
NCT02068196 2023-03-24
Ipi4
Oslo University Hospital
Phase 4 Active not recruiting
NCT02982954 2022-11-01
CHECKMATE 920
Bristol-Myers Squibb
Phase 4 Completed